Your Health, We Care
Release date: 2024-08-26 17:17:45 Recommended: 124
Alpelisib, approved in 2019, has a unique efficacy against PIK3CA mutant breast cancer. Alpelisib has become a key drug for the treatment of advanced breast cancer by blocking the PI3K signaling pathway to significantly delay the growth of tumors and improve the quality of life of patients.
Alpelisib plus fulvestrant has demonstrated significant efficacy in selected breast cancer patients.
Alpelisib in combination with fulvestrant demonstrated significant efficacy in patients with PIK3CA mutations, as assessed primarily by progression-free survival (PFS) and overall response rate (ORR). PFS results in the treatment group were consistent with blinded Independent Review Committee (BIRC) assessments, demonstrating effective disease control.
The combination of Alpelisib and fulvestrant has shown promising efficacy in selected breast cancer patients. A better understanding of medication considerations for special populations is essential to ensure that the course of treatment is fully managed.
Special attention needs to be paid to medication adjustment and monitoring in different populations when using Alpelisib.
There is a lack of data on the presence of Alpelisib in breast milk. Breastfeeding women are advised to stop breastfeeding during the medication and for a week after the last dose.
The effects of Alpelisib in patients with severe renal impairment are unclear. Patients with mild to moderate renal impairment do not need to adjust the dose.
Guidance on medication for special populations is critical. Other important medication considerations also need to be taken into account.
Medication considerations include details and potential risks that need to be paid special attention to when using the drug.
If severe symptoms of hypersensitivity occur, such as rash, difficulty breathing, or swelling of the face, Apelix must be discontinued immediately and used permanently. Patients should be aware of how these symptoms manifest and seek prompt medical attention if they occur.
Fasting blood glucose (FPG) and HbA1c should be measured before treatment to optimize glycemic control. After treatment, fasting blood glucose is monitored at least once a week for the first two weeks and every four weeks thereafter. High-risk patients, such as those who are obese or on systemic corticosteroids, should monitor their blood glucose more frequently and adjust their treatment regimens.
The above are the main precautions when using Alpelisib, and care should be taken to make appropriate monitoring and adjustments during treatment.
[Warm tips] During treatment, it is very important to maintain a positive mindset for recovery, and actively cooperate with the treatment and seek support and help to help improve the treatment effect and quality of life.
